Down-regulation of PAR1 activity with a pHLIP-based allosteric antagonist induces cancer cell death

Biochemical Journal

Volumn 472, Issue 3, 2015, Pages 287-295

  Burns, Kelly E ^a   Thevenin, Damien ^a  

^a LEHIGH UNIVERSITY   (United States)

Author keywords

Allosteric receptor modulation; Cancer cytotoxicity; G protein coupled receptor (GPCR); Intracellular loops; Peptide; Targeted drug delivery; Tumour acidity.

Indexed keywords

ANTINEOPLASTIC AGENT; G PROTEIN COUPLED RECEPTOR; LIPOSOME; MEMBRANE RECEPTOR; PEPTIDE; PEPTIDE FRAGMENT; PH LOW INSERTION PEPTIDE; PROTEINASE ACTIVATED RECEPTOR 1; TRYPTOPHAN; UNCLASSIFIED DRUG; MEMBRANE PROTEIN; PHLIP PROTEIN; TUMOR PROTEIN;

ACIDITY; ALLOSTERISM; AMINO TERMINAL SEQUENCE; ARTICLE; CANCER CELL; CELL DEATH; CELL SURFACE; CONCENTRATION (PARAMETERS); CONJUGATION; CYTOTOXICITY; DOWN REGULATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; PH; PRIORITY JOURNAL; SOLID TUMOR; TECHNOLOGY; BIOSYNTHESIS; DRUG EFFECTS; GENE EXPRESSION REGULATION; HELA CELL LINE; MCF-7 CELL LINE; METABOLISM; NEOPLASMS; PATHOLOGY;

CELL DEATH; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HELA CELLS; HUMANS; HYDROGEN-ION CONCENTRATION; MCF-7 CELLS; MEMBRANE PROTEINS; NEOPLASM PROTEINS; NEOPLASMS; RECEPTOR, PAR-1;

EID: 84955515561     PISSN: 02646021     EISSN: 14708728     Source Type: Journal    
DOI: 10.1042/BJ20150876     Document Type: Article

References (33)

1. Gether, U. And Kobilka, B.K. (1998) G protein-coupled receptors. II. Mechanism of agonist activation. J. Biol. Chem. 273, 17979-17982
2. Conn, P.J., Christopoulos, A. And Lindsley, C.W. (2009) Allosteric modulators of GPCRs: A novel approach for the treatment of CNS disorders. Nat. Rev. Drug Discov. 8, 41-54
3. Dimond, P., Carlson, K., Bouvier, M., Gerard, C., Xu, L., Covic, L., Agarwal, A., Ernst, O.P., Janz, J.M., Schwartz, T.W. et al. (2011) G protein-coupled receptor modulation with pepducins: moving closer to the clinic. Ann. N.Y. Acad. Sci. 1226, 34-49
4. Eglen, R.M. And Reisine, T. (2011) GPCRs revisited: new insights lead to novel drugs. Pharmaceuticals 4, 244-272
5. Canals, M., Sexton, P.M. And Christopoulos, A. (2011) Allostery in GPCRs: "MWC" revisited. Trends Biochem. Sci. 36, 663-672
6. Covic, L., Gresser, A.L., Talavera, J., Swift, S. And Kuliopulos, A. (2002) Activation and inhibition of G protein-coupled receptors by cell-penetrating membrane-Tethered peptides. Proc. Natl. Acad. Sci. U.S.A. 99, 643-648
7. Kostenis, E.E., Zeng, F.Y.F. And Wess, J.J. (1998) Functional characterization of a series of mutant G protein alphaq subunits displaying promiscuous receptor coupling properties. J. Biol. Chem. 273, 17886-17892
8. Cotecchia, S., Ostrowski, J., Kjelsberg, M.A., Caron, M.G. And Lefkowitz, R.J. (1992) Discrete amino acid sequences of the alpha 1-Adrenergic receptor determine the selectivity of coupling to phosphatidylinositol hydrolysis. J. Biol. Chem. 267, 1633-1639
9. O'Callaghan, K., Kuliopulos, A. And Covic, L. (2012) Turning receptors on and off with intracellular pepducins: new insights into G-protein-coupled receptor drug development. J. Biol. Chem. 287, 12787-12796
10. Agarwal, A., Covic, L., Sevigny, L.M., Kaneider, N.C., Lazarides, K., Azabdaftari, G., Sharifi, S. And Kuliopulos, A. (2008) Targeting a metalloprotease-PAR1 signaling system with cell-penetrating pepducins inhibits angiogenesis, ascites, and progression of ovarian cancer. Mol. Cancer Ther. 7, 2746-2757
11. Yang, E., Boire, A., Agarwal, A., Nguyen, N., O'Callaghan, K., Tu, P., Kuliopulos, A. And Covic, L. (2009) Blockade of PAR1 signaling with cell-penetrating pepducins inhibits Akt survival pathways in breast cancer cells and suppresses tumor survival and metastasis. Cancer Res. 69, 6223-6231
12. Miller, J., Doss, M., McQuillen, R., Shaller, C.C., Tolner, B., Yu, J.Q., Chester, K. And Robinson, M.K. (2012) Impact of expression system on the function of the C6.5 diabody PET radiotracer. Tumour Biol. 33, 617-627
13. Tressel, S.L., Koukos, G., Tchernychev, B., Jacques, S.L., Covic, L. And Kuliopulos, A. (2011) Pharmacology, biodistribution, and efficacy of GPCR-based pepducins in disease models. Methods Mol. Biol. 683, 259-275
14. Ossovskaya, V.S. And Bunnett, N.W. (2004) Protease-Activated receptors: contribution to physiology and disease. Physiol. Rev. 84, 579-621
15. Sevigny, L.M., Zhang, P., Bohm, A., Lazarides, K., Perides, G., Covic, L. And Kuliopulos, A. (2011) Interdicting protease-Activated receptor-2-driven inflammation with cell-penetrating pepducins. Proc. Natl. Acad. Sci. U.S.A. 108, 8491-8496
16. Boire, A., Covic, L., Agarwal, A., Jacques, S., Sherifi, S. And Kuliopulos, A. (2005) PAR1 Is a Matrix Metalloprotease-1 receptor that promotes invasion and Tumorigenesis of breast cancer cells. Cell 120, 11-11
17. Kamath, L., Meydani, A., Foss, F. And Kuliopulos, A. (2001) Signaling from protease-Activated receptor-1 inhibits migration and invasion of breast cancer cells. Cancer Res. 61, 5933-5940
18. Even-Ram, S., Uziely, B., Cohen, P., Grisaru-Granovsky, S., Maoz, M., Ginzburg, Y., Reich, R., Vlodavsky, I. And Bar-Shavit, R. (1998) Thrombin receptor overexpression in malignant and physiological invasion processes. Nat. Med. 4, 909-914
19. Granovsky-Grisaru, S., Zaidoun, S., Grisaru, D., Yekel, Y., Prus, D., Beller, U. And Bar-Shavit, R. (2006) The pattern of Protease Activated Receptor 1 (PAR1) expression in endometrial carcinoma. Gynecol. Oncol. 103, 802-806
20. Grisaru-Granovsky, S., Salah, Z., Maoz, M., Pruss, D., Beller, U. And Bar-Shavit, R. (2005) Differential expression of protease activated receptor 1 (Par1) and pY397FAK in benign and malignant human ovarian tissue samples. Int. J. Cancer 113, 372-378
21. Heider, I., Schulze, B., Oswald, E., Henklein, P., Scheele, J. And Kaufmann, R. (2004) PAR1-Type thrombin receptor stimulates migration and matrix adhesion of human colon carcinoma cells by a PKCepsilon-dependent mechanism. Oncol. Res. 14, 475-482
22. Nierodzik, M.L., Kajumo, F. And Karpatkin, S. (1992) Effect of thrombin treatment of tumor cells on adhesion of tumor cells to platelets in vitro and tumor metastasis in vivo. Cancer Res. 52, 3267-3272
23. Thevenin, D., An, M. And Engelman, D.M. (2009) pHLIP-mediated translocation of membrane-impermeable molecules into cells. Chem. Biol. 16, 754-762
24. An, M., Wijesinghe, D., Andreev, O.A., Reshetnyak, Y.K. And Engelman, D.M. (2010) pH-(low)-insertion-peptide (pHLIP) translocation of membrane impermeable phalloidin toxin inhibits cancer cell proliferation. Proc. Natl. Acad. Sci. U.S.A. 107, 20246-20250
25. Burns, K.E., Robinson, M.K. And Thevenin, D. (2015) Inhibition of cancer cell proliferation and breast tumor targeting of pHLIP-Monomethyl Auristatin E conjugates. Mol. Pharm. 12, 1250-1258
26. Reshetnyak, Y.K., Andreev, O.A., Lehnert, U. And Engelman, D.M. (2006) Translocation of molecules into cells by pH-dependent insertion of a transmembrane helix. Proc. Natl. Acad. Sci. U.S.A. 103, 6460-6465
27. Zoonens, M., Reshetnyak, Y.K. And Engelman, D.M. (2008) Bilayer interactions of pHLIP, a peptide that can deliver drugs and target tumors. Biophys. J. 95, 225-235
28. Fink, L.S., Beatty, A., Devarajan, K., Peri, S. And Peterson, J.R. (2015) Pharmacological profiling of kinase dependency in cell lines across triple-negative breast cancer subtypes. Mol. Cancer Ther. 14, 298-306
29. Goldenberg, M.M. (1999) Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. Clin. Ther. 21, 309-318
30. Jordan, V.C. And Brodie, A.M.H. (2007) Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer. Steroids 72, 7-25
31. Perou, C.M., Sørlie, T., Eisen, M.B., van de Rijn, M., Jeffrey, S.S., Rees, C.A., Pollack, J.R., Ross, D.T., Johnsen, H., Akslen, L.A. et al. (2000) Molecular portraits of human breast tumours. Nature 406, 747-752
32. Dent, R., Trudeau, M., Pritchard, K.I., Hanna, W.M., Kahn, H.K., Sawka, C.A., Lickley, L.A., Rawlinson, E., Sun, P. And Narod, S.A. (2007) Triple-negative breast cancer: clinical features and patterns of recurrence. Clin. Cancer Res. 13, 4429-4434
33. Jorgensen, W.L. And Duffy, E.M. (2002) Prediction of drug solubility from structure. Adv. Drug Deliv. Rev. 54, 355-366